Daniel J. Asby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel J. Asby has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ali Tavassoli
University of Southampton
5 shared publications - James Scott Miners
University of Bristol
4 shared publications - Delphine Boche
Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
2 shared publications F. Cuda
Chemistry, University of Southampton, Southampton, SO17 1BJ, UK.
2 shared publicationsSeth Love
Translational Health Sciences, Cerebrovascular & Dementia Research Group, Bristol Medical School, University of Bristol , Bristol, BS10 5NB
2 shared publications- Wiebke Arlt
Medical Research Council Laboratory of Medical Sciences, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1497-1508
Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study
Background: Evidence suggests that dysregulation of the renin angiotensin system (RAS) is associated with the pathophysiologic process of Alzheimer's disease (AD). Few studies have evaluated the relationship between circulating RAS components and incident cognitive decline or impairment. Objective: Our study aims to evaluate the relationship between circulating RAS biomarkers (angiotensin II [ANGII], angiotensin 1-7 [ANG1-7], angiotensin converting enzyme-1 [ACE-1], and 2 [ACE-2]), in initially cognitively healthy adults, and incident cognitive decline and cognitive impairment. Methods: In this secondary analysis, 310 community-dwelling participants from the randomized controlled Action for Health in Diabetes (Look AHEAD) study without dementia, who were not on RAS-altering medication, were included. Results: Participants, compared to those excluded, were more likely to be female (65%), white (76%), overweight (34%), have lower baseline HbA1c (6.7%), lower SBP (119.7 mmHg), lower serum creatinine (0.79 mg/dL), higher total cholesterol (190.1 mg/dL) and LDL (112.5 mg/dL), and higher history of dyslipidemia (65%) at baseline. 1 SD increase of ANG1-7 measured in year 1 was associated with lower odds of cognitive impairment (OR = 0.35, 95% CI 0.16-0.77; p = 0.001), while higher ANG1-7 levels predicted better global cognitive function [β x 10 −3 = 1.03 (0.50); p = 0.039], 15 years later. Conclusions: These results provide preliminary evidence that circulating RAS components are predictive of protection against cognitive impairment and decline and may serve as a marker of the early stages of dementia. Further research is warranted to fully understand the relationship between the brain and the circulatory RAS.
- 18 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1497-1508
Open AccessAssociation between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study
Background: Evidence suggests that dysregulation of the renin angiotensin system (RAS) is associated with the pathophysiologic process of Alzheimer's disease (AD). Few studies have evaluated the relationship between circulating RAS components and incident cognitive decline or impairment. Objective: Our study aims to evaluate the relationship between circulating RAS biomarkers (angiotensin II [ANGII], angiotensin 1-7 [ANG1-7], angiotensin converting enzyme-1 [ACE-1], and 2 [ACE-2]), in initially cognitively healthy adults, and incident cognitive decline and cognitive impairment. Methods: In this secondary analysis, 310 community-dwelling participants from the randomized controlled Action for Health in Diabetes (Look AHEAD) study without dementia, who were not on RAS-altering medication, were included. Results: Participants, compared to those excluded, were more likely to be female (65%), white (76%), overweight (34%), have lower baseline HbA1c (6.7%), lower SBP (119.7 mmHg), lower serum creatinine (0.79 mg/dL), higher total cholesterol (190.1 mg/dL) and LDL (112.5 mg/dL), and higher history of dyslipidemia (65%) at baseline. 1 SD increase of ANG1-7 measured in year 1 was associated with lower odds of cognitive impairment (OR = 0.35, 95% CI 0.16-0.77; p = 0.001), while higher ANG1-7 levels predicted better global cognitive function [β x 10 −3 = 1.03 (0.50); p = 0.039], 15 years later. Conclusions: These results provide preliminary evidence that circulating RAS components are predictive of protection against cognitive impairment and decline and may serve as a marker of the early stages of dementia. Further research is warranted to fully understand the relationship between the brain and the circulatory RAS.
- Open Access
- 30 November 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (3) , e70052
Vessel‐associated microglia are differentially activated and distributed in relation to systemic infection and Alzheimer's disease
Vessel‐associated microglia (VAM) are an integral part of the neurovascular unit and have recently been implicated in the pathophysiology of cerebrovascular injury and blood–brain barrier (BBB) leakiness in Alzheimer's disease (AD). In this neuropathological study, we explored the hypothesis that the distribution and activation of VAM are altered in AD in the presence of systemic infection, associated with cerebrovascular dysfunction. We studied VAM density in the temporal cortex and underlying white matter from AD and age‐matched controls with and without terminal systemic infection (SI) ( n = 15 per group). The area of VAM labelled with microglial markers (Iba1, HLA‐DR, CD68) was quantified in proximity to CD31‐labelled microvessels within three predefined regions: contact VAM, proximity 15 μm. The relationships between VAM and previously measured brain cytokine levels and biochemical markers of cerebral perfusion (MAG:PLP1, endothelin‐1) and BBB leakiness (VEGF‐A and fibrinogen), were explored in a subset of cases. Compared to controls, the relative area of Iba1+ VAM was higher in SI and in AD. The area of HLA‐DR+ VAM was higher in AD only. The area of Iba1+ VAM that expressed CD68, a marker of phagocytosis, was higher in both AD and AD + SI. Iba1+ and HLA‐DR+ VAM correlated inversely with anti‐inflammatory cytokines (IL‐10, IL‐23) in AD and positively with pro‐inflammatory cytokines (IL‐6, IL‐23, GM‐CSF, IL‐17) in AD + SI. Iba1+ VAM density correlated positively with endothelin‐1, VEGF‐A and fibrinogen in controls. HLA‐DR+ VAM density correlated positively with Aβ 1‐42 in both controls and AD, and inversely with PDGFRβ and VCAM‐1 in AD. Our data reveal the distribution of VAM is elevated in AD, and altered in the presence of systemic infection, which together are likely to be independent and synergistic contributors to cerebrovascular dysfunction in AD.
- 30 November 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (3) , e70052
Open AccessVessel‐associated microglia are differentially activated and distributed in relation to systemic infection and Alzheimer's disease
Vessel‐associated microglia (VAM) are an integral part of the neurovascular unit and have recently been implicated in the pathophysiology of cerebrovascular injury and blood–brain barrier (BBB) leakiness in Alzheimer's disease (AD). In this neuropathological study, we explored the hypothesis that the distribution and activation of VAM are altered in AD in the presence of systemic infection, associated with cerebrovascular dysfunction. We studied VAM density in the temporal cortex and underlying white matter from AD and age‐matched controls with and without terminal systemic infection (SI) ( n = 15 per group). The area of VAM labelled with microglial markers (Iba1, HLA‐DR, CD68) was quantified in proximity to CD31‐labelled microvessels within three predefined regions: contact VAM, proximity 15 μm. The relationships between VAM and previously measured brain cytokine levels and biochemical markers of cerebral perfusion (MAG:PLP1, endothelin‐1) and BBB leakiness (VEGF‐A and fibrinogen), were explored in a subset of cases. Compared to controls, the relative area of Iba1+ VAM was higher in SI and in AD. The area of HLA‐DR+ VAM was higher in AD only. The area of Iba1+ VAM that expressed CD68, a marker of phagocytosis, was higher in both AD and AD + SI. Iba1+ and HLA‐DR+ VAM correlated inversely with anti‐inflammatory cytokines (IL‐10, IL‐23) in AD and positively with pro‐inflammatory cytokines (IL‐6, IL‐23, GM‐CSF, IL‐17) in AD + SI. Iba1+ VAM density correlated positively with endothelin‐1, VEGF‐A and fibrinogen in controls. HLA‐DR+ VAM density correlated positively with Aβ 1‐42 in both controls and AD, and inversely with PDGFRβ and VCAM‐1 in AD. Our data reveal the distribution of VAM is elevated in AD, and altered in the presence of systemic infection, which together are likely to be independent and synergistic contributors to cerebrovascular dysfunction in AD.
- Open Access
- 22 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1182-1193
Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer’s disease
Cerebral hypoperfusion and blood–brain barrier (BBB) leakiness are pathological features of Alzheimer’s disease (AD). To understand their relationship to the distribution and progression of Alzheimer’s disease neuropathologic change (ADNC), we analysed associations between biochemical markers and mediators of cerebral hypoperfusion and BBB leakiness, and amyloid-β (Aβ) and hyperphosphorylated tau, in multiple brain regions at different Braak tangle stages (BS). We studied the frontal, temporal, parietal, entorhinal, calcarine and cingulate cortex, putamen and trigonal white matter from eight controls with low pathology (BS0–II), 17 brains with early-stage/intermediate AD pathology (BSIII–IV) and 11 late-stage AD cases (BSV–VI), from the South West Dementia Brain Bank and the London Neurodegenerative Diseases Brain Bank. We excluded cases with widespread moderate-severe arteriolosclerosis, macroscopic infarcts or foci of haemorrhage, Lewy body pathology or other neurodegenerative pathology. ELISAs were used to measure the myelin-associated glycoprotein:proteolipid protein-1 ratio (MAG:PLP1), an index of ante-mortem cerebral perfusion, and fibrinogen levels, to assess BBB leakiness. Also by ELISA, we measured vascular endothelial growth factor-A (VEGF-A), upregulated in cerebral ischaemia; endothelin-1 (EDN1), a mediator of vasoconstriction; CD31, an endothelial marker; platelet-derived growth factor-β (PDGFRβ), a pericyte marker; and Aβ1-40, Aβ1–42 and ptau-231 concentrations. In the temporal cortex from a subset of cases, 55 angiogenesis-related proteins were assayed using a multiplex profiler assay. MAG:PLP1 was lower in BSIII–IV than BS0–II in all brain regions. VEGF-A, EDN1 and CD31 concentrations were highest in BSIII–IV in most regions and correlated inversely with MAG:PLP1. EDN1 level correlated strongly with Aβ1–42 concentration in low-pathology controls. Angiogenesis-related protein assays showed elevated levels of endoglin (CD105), a marker of neoangiogenesis, in BSIII–IV, coinciding with altered expression of several angiogenic mediators. The PDGFRβ:CD31 ratio, a marker of pericyte content adjusted for vessel density, was lower in BSIII–IV than BS0–II and correlated positively with MAG:PLP1 and inversely with Aβ1–42. BBB leakiness, evidenced by elevated fibrinogen in brain tissue homogenates, was highest in BSV–VI in most brain regions and correlated with VEGF-A, CD31 and ptau-231 concentrations. The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD. The study highlights a complex and dynamic temporal relationship, beginning in early-stage AD, between mediators of cerebrovascular dysfunction and the regional spread of Aβ and tau pathology. The study also identifies several therapeutic targets, including EDN1 and VEGF-A signalling, with the potential to limit cerebrovascular damage in early AD.
- 22 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1182-1193
Open AccessPost-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer’s disease
Cerebral hypoperfusion and blood–brain barrier (BBB) leakiness are pathological features of Alzheimer’s disease (AD). To understand their relationship to the distribution and progression of Alzheimer’s disease neuropathologic change (ADNC), we analysed associations between biochemical markers and mediators of cerebral hypoperfusion and BBB leakiness, and amyloid-β (Aβ) and hyperphosphorylated tau, in multiple brain regions at different Braak tangle stages (BS). We studied the frontal, temporal, parietal, entorhinal, calcarine and cingulate cortex, putamen and trigonal white matter from eight controls with low pathology (BS0–II), 17 brains with early-stage/intermediate AD pathology (BSIII–IV) and 11 late-stage AD cases (BSV–VI), from the South West Dementia Brain Bank and the London Neurodegenerative Diseases Brain Bank. We excluded cases with widespread moderate-severe arteriolosclerosis, macroscopic infarcts or foci of haemorrhage, Lewy body pathology or other neurodegenerative pathology. ELISAs were used to measure the myelin-associated glycoprotein:proteolipid protein-1 ratio (MAG:PLP1), an index of ante-mortem cerebral perfusion, and fibrinogen levels, to assess BBB leakiness. Also by ELISA, we measured vascular endothelial growth factor-A (VEGF-A), upregulated in cerebral ischaemia; endothelin-1 (EDN1), a mediator of vasoconstriction; CD31, an endothelial marker; platelet-derived growth factor-β (PDGFRβ), a pericyte marker; and Aβ1-40, Aβ1–42 and ptau-231 concentrations. In the temporal cortex from a subset of cases, 55 angiogenesis-related proteins were assayed using a multiplex profiler assay. MAG:PLP1 was lower in BSIII–IV than BS0–II in all brain regions. VEGF-A, EDN1 and CD31 concentrations were highest in BSIII–IV in most regions and correlated inversely with MAG:PLP1. EDN1 level correlated strongly with Aβ1–42 concentration in low-pathology controls. Angiogenesis-related protein assays showed elevated levels of endoglin (CD105), a marker of neoangiogenesis, in BSIII–IV, coinciding with altered expression of several angiogenic mediators. The PDGFRβ:CD31 ratio, a marker of pericyte content adjusted for vessel density, was lower in BSIII–IV than BS0–II and correlated positively with MAG:PLP1 and inversely with Aβ1–42. BBB leakiness, evidenced by elevated fibrinogen in brain tissue homogenates, was highest in BSV–VI in most brain regions and correlated with VEGF-A, CD31 and ptau-231 concentrations. The present data provide evidence of widespread cerebral hypoperfusion associated with pathogenic angiogenesis and vascular remodelling in AD. The study highlights a complex and dynamic temporal relationship, beginning in early-stage AD, between mediators of cerebrovascular dysfunction and the regional spread of Aβ and tau pathology. The study also identifies several therapeutic targets, including EDN1 and VEGF-A signalling, with the potential to limit cerebrovascular damage in early AD.
- Open Access
- 16 March 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (6) , 1869-1883
Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease
We studied the effects of systemic infection on brain cytokine level and cerebral vascular function in Alzheimer’s disease and vascular dementia, in superior temporal cortex (Brodmann area 22) from Alzheimer’s disease patients (n = 75), vascular dementia patients (n = 22) and age-matched control subjects (n = 46), stratified according to the presence or absence of terminal systemic infection. Brain cytokine levels were measured using Mesoscale Discovery Multiplex Assays and markers of cerebrovascular function were assessed by ELISA. Multiple brain cytokines were elevated in Alzheimer’s disease and vascular dementia: IL-15 and IL-17A were maximally elevated in end-stage Alzheimer’s disease (Braak tangle stage V–VI) whereas IL-2, IL-5, IL12p40 and IL-16 were highest in intermediate Braak tangle stage III–IV disease. Several cytokines (IL-1β, IL-6, TNF-α, IL-8 and IL-15) were further raised in Alzheimer’s disease with systemic infection. Cerebral hypoperfusion—indicated by decreased MAG:PLP1 and increased vascular endothelial growth factor-A (VEGF)—and blood–brain barrier leakiness, indicated by raised levels of fibrinogen, were exacerbated in Alzheimer’s disease and vascular dementia patients, and also in non-dementia controls, with systemic infection. Amyloid-β42 level did not vary with infection or in association with brain cytokine levels. In controls, cortical perfusion declined with increasing IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13 and tumour necrosis factor-α (TNF-α) but these relationships were lost with progression of Alzheimer’s disease, and with infection (even in Braak stage 0–II brains). Cortical platelet-derived growth factor receptor-β (PDGFRβ), a pericyte marker, was reduced, and endothelin-1 (EDN1) level was increased in Alzheimer’s disease; these were related to amyloid-β level and disease progression and only modestly affected by systemic infection. Our findings indicate that systemic infection alters brain cytokine levels and exacerbates cerebral hypoperfusion and blood–brain barrier leakiness associated with Alzheimer’s disease and vascular dementia, independently of the level of insoluble amyloid-β, and highlight systemic infection as an important contributor to dementia, requiring early identification and treatment in the elderly population.
- 16 March 2021
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (6) , 1869-1883
Open AccessSystemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease
We studied the effects of systemic infection on brain cytokine level and cerebral vascular function in Alzheimer’s disease and vascular dementia, in superior temporal cortex (Brodmann area 22) from Alzheimer’s disease patients (n = 75), vascular dementia patients (n = 22) and age-matched control subjects (n = 46), stratified according to the presence or absence of terminal systemic infection. Brain cytokine levels were measured using Mesoscale Discovery Multiplex Assays and markers of cerebrovascular function were assessed by ELISA. Multiple brain cytokines were elevated in Alzheimer’s disease and vascular dementia: IL-15 and IL-17A were maximally elevated in end-stage Alzheimer’s disease (Braak tangle stage V–VI) whereas IL-2, IL-5, IL12p40 and IL-16 were highest in intermediate Braak tangle stage III–IV disease. Several cytokines (IL-1β, IL-6, TNF-α, IL-8 and IL-15) were further raised in Alzheimer’s disease with systemic infection. Cerebral hypoperfusion—indicated by decreased MAG:PLP1 and increased vascular endothelial growth factor-A (VEGF)—and blood–brain barrier leakiness, indicated by raised levels of fibrinogen, were exacerbated in Alzheimer’s disease and vascular dementia patients, and also in non-dementia controls, with systemic infection. Amyloid-β42 level did not vary with infection or in association with brain cytokine levels. In controls, cortical perfusion declined with increasing IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13 and tumour necrosis factor-α (TNF-α) but these relationships were lost with progression of Alzheimer’s disease, and with infection (even in Braak stage 0–II brains). Cortical platelet-derived growth factor receptor-β (PDGFRβ), a pericyte marker, was reduced, and endothelin-1 (EDN1) level was increased in Alzheimer’s disease; these were related to amyloid-β level and disease progression and only modestly affected by systemic infection. Our findings indicate that systemic infection alters brain cytokine levels and exacerbates cerebral hypoperfusion and blood–brain barrier leakiness associated with Alzheimer’s disease and vascular dementia, independently of the level of insoluble amyloid-β, and highlight systemic infection as an important contributor to dementia, requiring early identification and treatment in the elderly population.
- Open Access
- 14 October 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (44) , 22294-22299
Alternative pathway androgen biosynthesis and human fetal female virilization
Significance: In the classic androgen biosynthesis pathway, testosterone is converted to 5α-dihydrotestosterone, a step crucially required for normal male genital virilization. Congenital adrenal hyperplasia (CAH) due to P450 oxidoreductase deficiency (PORD) is an inborn disorder that disrupts classic androgen biosynthesis. However, some affected girls present with severe genital virilization at birth. We hypothesized that this is explained by a prenatally active, alternative biosynthesis pathway to 5α-dihydrotestosterone. We show that adrenals and genital skin cooperate to produce androgens via the alternative pathway during the major period of human sexual differentiation and that neonates with PORD still produce alternative pathway androgens during the first weeks of life. This indicates that alternative pathway androgen biosynthesis drives prenatal virilization in CAH due to PORD.
- 14 October 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (44) , 22294-22299
Open AccessAlternative pathway androgen biosynthesis and human fetal female virilization
Significance: In the classic androgen biosynthesis pathway, testosterone is converted to 5α-dihydrotestosterone, a step crucially required for normal male genital virilization. Congenital adrenal hyperplasia (CAH) due to P450 oxidoreductase deficiency (PORD) is an inborn disorder that disrupts classic androgen biosynthesis. However, some affected girls present with severe genital virilization at birth. We hypothesized that this is explained by a prenatally active, alternative biosynthesis pathway to 5α-dihydrotestosterone. We show that adrenals and genital skin cooperate to produce androgens via the alternative pathway during the major period of human sexual differentiation and that neonates with PORD still produce alternative pathway androgens during the first weeks of life. This indicates that alternative pathway androgen biosynthesis drives prenatal virilization in CAH due to PORD.
- Open Access
- 1 September 2018
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 3483-3500
Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
Background: Diffuse intrinsic pontine glioma (DIPG) is a lethal type of pediatric brain tumor that is resistant to conventional chemotherapies. Palbociclib is a putative novel DIPG treatment that restricts the proliferation of rapidly dividing cancer cells via selective inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. However, implementing palbociclib as a monotherapy for DIPG is unfeasible, as CDK4/6 inhibitor resistance is commonplace and palbociclib does not readily cross the blood–brain barrier (BBB) or persist in the central nervous system. To inhibit the growth of DIPG cells, we aimed to use palbociclib in combination with the rapamycin analog temsirolimus, which is known to ameliorate resistance to CDK4/6 inhibitors and inhibit BBB efflux. Materials and methods: We tested palbociclib and temsirolimus in three patient-derived DIPG cell lines. The expression profiles of key proteins in the CDK4/6 and mammalian target of rapamycin (mTOR) signaling pathways were assessed, respectively, to determine feasibility against DIPG. Moreover, we investigated effects on cell viability and examined in vivo drug toxicity. Results: Immunoblot analyses revealed palbociclib and temsirolimus inhibited CDK4/6 and mTOR signaling through canonical perturbation of phosphorylation of the retinoblastoma (RB) and mTOR proteins, respectively; however, we observed noncanonical downregulation of mTOR by palbociclib. We demonstrated that palbociclib and temsirolimus inhibited cell proliferation in all three DIPG cell lines, acting synergistically in combination to further restrict cell growth. Flow cytometric analyses revealed both drugs caused G1 cell cycle arrest, and clonogenic assays showed irreversible effects on cell proliferation. Palbociclib did not elicit neurotoxicity in primary cultures of normal rat hippocampi or when infused into rat brains. Conclusion: These data illustrate the in vitro antiproliferative effects of CDK4/6 and mTOR inhibitors in DIPG cells. Direct infusion of palbociclib into the brain, in combination with systemic delivery of temsirolimus, represents a promising new approach to developing a much-needed treatment for DIPG.
- 1 September 2018
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 3483-3500
Open AccessCombined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
Background: Diffuse intrinsic pontine glioma (DIPG) is a lethal type of pediatric brain tumor that is resistant to conventional chemotherapies. Palbociclib is a putative novel DIPG treatment that restricts the proliferation of rapidly dividing cancer cells via selective inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. However, implementing palbociclib as a monotherapy for DIPG is unfeasible, as CDK4/6 inhibitor resistance is commonplace and palbociclib does not readily cross the blood–brain barrier (BBB) or persist in the central nervous system. To inhibit the growth of DIPG cells, we aimed to use palbociclib in combination with the rapamycin analog temsirolimus, which is known to ameliorate resistance to CDK4/6 inhibitors and inhibit BBB efflux. Materials and methods: We tested palbociclib and temsirolimus in three patient-derived DIPG cell lines. The expression profiles of key proteins in the CDK4/6 and mammalian target of rapamycin (mTOR) signaling pathways were assessed, respectively, to determine feasibility against DIPG. Moreover, we investigated effects on cell viability and examined in vivo drug toxicity. Results: Immunoblot analyses revealed palbociclib and temsirolimus inhibited CDK4/6 and mTOR signaling through canonical perturbation of phosphorylation of the retinoblastoma (RB) and mTOR proteins, respectively; however, we observed noncanonical downregulation of mTOR by palbociclib. We demonstrated that palbociclib and temsirolimus inhibited cell proliferation in all three DIPG cell lines, acting synergistically in combination to further restrict cell growth. Flow cytometric analyses revealed both drugs caused G1 cell cycle arrest, and clonogenic assays showed irreversible effects on cell proliferation. Palbociclib did not elicit neurotoxicity in primary cultures of normal rat hippocampi or when infused into rat brains. Conclusion: These data illustrate the in vitro antiproliferative effects of CDK4/6 and mTOR inhibitors in DIPG cells. Direct infusion of palbociclib into the brain, in combination with systemic delivery of temsirolimus, represents a promising new approach to developing a much-needed treatment for DIPG.
- Open Access
- 25 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0176855
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma
Targeting epigenetic changes in diffuse intrinsic pontine glioma (DIPG) may provide a novel treatment option for patients. This report demonstrates that sodium valproate, a histone deacetylase inhibitor (HDACi), can increase the cytotoxicity of carboplatin in an additive and synergistic manner in DIPG cells in vitro. Sodium valproate causes a dose-dependent decrease in DIPG cell viability in three independent ex vivo cell lines. Furthermore, sodium valproate caused an increase in acetylation of histone H3. Changes in cell viability were consistent with an induction of apoptosis in DIPG cells in vitro, determined by flow cytometric analysis of Annexin V staining and assessment of apoptotic markers by western blotting. Subsequently, immunofluorescent staining of neuronal and glial markers was used to determine toxicity in normal rat hippocampal cells. Pre-treatment of cells with sodium valproate enhanced the cytotoxic effects of carboplatin, in three DIPG cell lines tested. These results demonstrate that sodium valproate causes increased histone H3 acetylation indicative of HDAC inhibition, which is inversely correlated with a reduction in cell viability. Cell viability is reduced through an induction of apoptosis in DIPG cells. Sodium valproate potentiates carboplatin cytotoxicity and prompts further work to define the mechanism responsible for the synergy between these two drugs and determine in vivo efficacy. These findings support the use of sodium valproate as an adjuvant treatment for DIPG.
- 25 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0176855
Open AccessRepurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma
Targeting epigenetic changes in diffuse intrinsic pontine glioma (DIPG) may provide a novel treatment option for patients. This report demonstrates that sodium valproate, a histone deacetylase inhibitor (HDACi), can increase the cytotoxicity of carboplatin in an additive and synergistic manner in DIPG cells in vitro. Sodium valproate causes a dose-dependent decrease in DIPG cell viability in three independent ex vivo cell lines. Furthermore, sodium valproate caused an increase in acetylation of histone H3. Changes in cell viability were consistent with an induction of apoptosis in DIPG cells in vitro, determined by flow cytometric analysis of Annexin V staining and assessment of apoptotic markers by western blotting. Subsequently, immunofluorescent staining of neuronal and glial markers was used to determine toxicity in normal rat hippocampal cells. Pre-treatment of cells with sodium valproate enhanced the cytotoxic effects of carboplatin, in three DIPG cell lines tested. These results demonstrate that sodium valproate causes increased histone H3 acetylation indicative of HDAC inhibition, which is inversely correlated with a reduction in cell viability. Cell viability is reduced through an induction of apoptosis in DIPG cells. Sodium valproate potentiates carboplatin cytotoxicity and prompts further work to define the mechanism responsible for the synergy between these two drugs and determine in vivo efficacy. These findings support the use of sodium valproate as an adjuvant treatment for DIPG.
- 15 September 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (39) , 9322-9330
Triggering apoptosis in cancer cells with an analogue of cribrostatin 6 that elevates intracellular ROS
A synthetic analogue of the marine natural product cribrostatin 6 is synthesized that selectively triggers apoptosis in cancer cells via elevation of intracellular ROS.
- 15 September 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (39) , 9322-9330
Triggering apoptosis in cancer cells with an analogue of cribrostatin 6 that elevates intracellular ROS
A synthetic analogue of the marine natural product cribrostatin 6 is synthesized that selectively triggers apoptosis in cancer cells via elevation of intracellular ROS.
- Open Access
- 1 February 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (9) , 2645-2650
Perenosins: a new class of anion transporter with anti-cancer activity
A new class of anion transporter named ‘perenosins’ consisting of a pyrrole linked through an imine to either an indole, benzimidazole or indazole is reported. The indole containing members of the perenosin family function as effective transmembrane Cl−/NO3 − antiporters and HCl cotransporters in a manner similar to the prodigiosenes. The compounds reduce the viability of MDA-MB-231 and MCF-7.
- 1 February 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (9) , 2645-2650
Open AccessPerenosins: a new class of anion transporter with anti-cancer activity
A new class of anion transporter named ‘perenosins’ consisting of a pyrrole linked through an imine to either an indole, benzimidazole or indazole is reported. The indole containing members of the perenosin family function as effective transmembrane Cl−/NO3 − antiporters and HCl cotransporters in a manner similar to the prodigiosenes. The compounds reduce the viability of MDA-MB-231 and MCF-7.
- Open Access
- 1 July 2015
- Published by Elsevier in Chemistry & Biology
- Vol. 22 (7) , 838-848
AMPK Activation via Modulation of De Novo Purine Biosynthesis with an Inhibitor of ATIC Homodimerization
- 1 July 2015
- Published by Elsevier in Chemistry & Biology
- Vol. 22 (7) , 838-848
Open AccessAMPK Activation via Modulation of De Novo Purine Biosynthesis with an Inhibitor of ATIC Homodimerization